NVCR MEXC RealStocks
Own real NVCR shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 07:41:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
NovoCure Limited (NVCR) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $10.71, with a market capitalization of $1.30B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9.82 to $21.45. This page covers its latest market performance, valuation, price trends and company information.
$1.30B | |
$11.16 | |
$11.47 | |
$10.69 | |
$11.14 | |
1.12M | |
1.51M | |
-- | |
$21.45 | |
$9.82 | |
-- | |
2026-09-30 |
NovoCure Limited (NVCR) last closed at $10.71 as of 2026-11-19 00:53:00, down 3.86% ($0.43) from the previous close of $11.14.
During the latest regular trading session, NVCR traded between $10.69 and $11.47, with a volume of 1.12M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, NovoCure Limited (NVCR) moved from $11.81 to $10.71, representing a decline of 9.29% ($1.10).
The stock traded between $10.69 and $12.95 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.58 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 7.7%
NVCR is currently trading at $10.71, placing it 7.7% of the way from its 52-week low of $9.82 to its 52-week high of $21.45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 1,605 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of NovoCure Limited (NVCR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to NVCR, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between NVCR shares and USD.
NVCR Shares to USD
1.00 NVCR shares = 10.713 USD
Calculations are estimates based on the latest available price and are for reference only.